RxDoctor Payments Data

Lisa Gamell, MD

Ophthalmology · Tampa, FLNPI 1629051651

Payments from drug & device makers

$2,824in general payments, 2019–2025

Across 91 payments — averaging $31.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • NEW World Medical,inc.$649
  • AbbVie$309
  • Glaukos Corporation$268
  • Alcon$266
  • Sight Sciences, Inc.$194
  • Sun Pharmaceutical Industries Inc.$180
  • plus $958 from 13 others

What the payments were for

  • Food & beverage$2,74497%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,824 in reported general payments places this provider in the 55th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$156,280
Medicare patients
376
Services billed
2,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost116$61,430
RhopressaNetarsudil Mesylate71$36,896
CombiganBrimonidine Tartrate/Timolol51$22,245
Alphagan PBrimonidine Tartrate35$17,550
RocklatanNetarsudil Mesylat/Latanoprost22$16,872
SimbrinzaBrinzolamide/Brimonidine Tart52$16,220
VyzultaLatanoprostene Bunod31$12,766
RestasisCyclosporine12$12,591
Travoprost51$10,016
Brimonidine Tartrate212$8,353
Brinzolamide25$6,173
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$5,949
AzoptBrinzolamide12$5,444
Prednisolone Acetate116$4,841
Latanoprost458$4,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P, Restasis$309$113,815214 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$91$53,76993 claims
AlconSimbrinza, Azopt$266$21,66564 claims
Bausch & Lomb Americas Inc.Vyzulta$120$12,76631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →